Madrigal Pharma (NASDAQ: MDGL) reported Q3 EPS of ($5.34), $0.44 worse than the analyst estimate of ($4.90). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.